Consistent with these results, evodiamine also cleaved PARP and caspase 3 and decreased the anti-apoptotic protein Bcl-xL in HCC cells in a dose-dependent manner (Figure 4B and Supplementary Figure S2B) [22]. This evidence concerns the gene BCL2L1 and hepatocellular carcinoma.